MeSH term
Frequency | Condition_Probility | Humans | 500 | 0.0 |
Adult | 112 | 0.0 |
Aged | 115 | 0.0 |
Aged, 80 and over | 53 | 0.0 |
Chromosomes, Human, Pair 14/genetics | 6 | 7.0 |
Chromosomes, Human, Pair 18/genetics | 5 | 10.0 |
Female | 185 | 0.0 |
Follow-Up Studies | 10 | 0.0 |
In Situ Hybridization, Fluorescence | 31 | 1.0 |
Lymphoma, B-Cell/*genetics/pathology | 8 | 34.0 |
Male | 175 | 0.0 |
Middle Aged | 147 | 0.0 |
Neoplasm Proteins/genetics | 3 | 0.0 |
Prognosis | 50 | 0.0 |
Research Support, Non-U.S. Gov't | 322 | 0.0 |
*Translocation, Genetic | 54 | 6.0 |
*Trisomy | 2 | 1.0 |
Regression Analysis | 6 | 0.0 |
*Chromosomes, Human, Pair 14 | 17 | 9.0 |
*Chromosomes, Human, Pair 18 | 23 | 16.0 |
Genes, bcl-2 | 13 | 12.0 |
Genes, myc | 10 | 3.0 |
Lymphoma/*genetics | 7 | 14.0 |
Apoptosis/*physiology | 15 | 2.0 |
Flow Cytometry | 19 | 0.0 |
Predictive Value of Tests | 9 | 0.0 |
Pregnancy | 4 | 0.0 |
Apoptosis/drug effects/*physiology | 3 | 1.0 |
Neoplasm Invasiveness | 5 | 0.0 |
Protein p53/*metabolism | 10 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 26 | 10.0 |
Aneuploidy | 5 | 2.0 |
Animals | 113 | 0.0 |
Apoptosis/physiology | 6 | 1.0 |
Caspases/antagonists & inhibitors | 2 | 4.0 |
Cell Division/physiology | 6 | 0.0 |
Cyclins/metabolism | 3 | 0.0 |
Cytochrome c Group/metabolism | 4 | 2.0 |
Genes, Tumor Suppressor/*physiology | 2 | 1.0 |
Genes, cdc/physiology | 2 | 12.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Homozygote | 2 | 0.0 |
Mice | 66 | 0.0 |
Mice, Inbred C57BL | 6 | 0.0 |
Mice, Knockout | 3 | 0.0 |
Mice, Transgenic | 16 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Ploidies | 2 | 0.0 |
Protein p53/*physiology | 3 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 34 | 7.0 |
Research Support, U.S. Gov't, P.H.S. | 137 | 0.0 |
Cell Lineage | 3 | 0.0 |
Cell Separation | 6 | 0.0 |
Cell Survival | 14 | 1.0 |
Cycloheximide/pharmacology | 3 | 0.0 |
DNA-Binding Proteins/*metabolism | 6 | 0.0 |
Gene Expression Regulation | 10 | 0.0 |
Melanoma/*metabolism | 2 | 3.0 |
Models, Genetic | 5 | 0.0 |
Oligonucleotide Array Sequence Analysis | 10 | 0.0 |
Phenotype | 11 | 0.0 |
Phosphorylation | 28 | 0.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
Protein Binding | 3 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 3 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/genetics/*metabolism | 9 | 15.0 |
Signal Transduction | 14 | 0.0 |
Spleen/cytology | 2 | 1.0 |
Time Factors | 15 | 0.0 |
*Transcription Factors | 4 | 0.0 |
Transcription, Genetic | 5 | 0.0 |
Tumor Cells, Cultured | 81 | 0.0 |
*Apoptosis | 42 | 2.0 |
Cell Division/*drug effects | 3 | 1.0 |
Drug Screening Assays, Antitumor | 5 | 1.0 |
Antineoplastic Agents/*pharmacology | 9 | 0.0 |
Apoptosis/*drug effects | 28 | 3.0 |
Blotting, Western | 24 | 0.0 |
Caspases/genetics/metabolism | 2 | 13.0 |
Cell Division/drug effects | 13 | 0.0 |
Cell Survival/drug effects | 7 | 0.0 |
Dose-Response Relationship, Drug | 11 | 0.0 |
Proto-Oncogene Proteins/metabolism | 16 | 1.0 |
Drug Resistance, Neoplasm | 7 | 1.0 |
Oligonucleotides, Antisense/*pharmacology | 2 | 2.0 |
Up-Regulation | 11 | 0.0 |
Chromosome Aberrations | 9 | 1.0 |
In Situ Hybridization, Fluorescence/*methods | 3 | 3.0 |
Base Sequence | 48 | 0.0 |
Gene Rearrangement, B-Lymphocyte | 4 | 7.0 |
*Genes, Immunoglobulin | 13 | 6.0 |
Immunoglobulin Variable Region/genetics | 3 | 2.0 |
Immunoglobulins, Heavy-Chain/genetics | 8 | 5.0 |
Leukemia, B-Cell, Chronic/*genetics | 6 | 15.0 |
Molecular Sequence Data | 45 | 0.0 |
Mutation | 13 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Translocation, Genetic | 28 | 3.0 |
Genes, bcl-2/*genetics | 5 | 19.0 |
Genes, p53/*genetics | 5 | 1.0 |
Immunohistochemistry | 81 | 0.0 |
Prospective Studies | 3 | 0.0 |
Immunoglobulins, Heavy-Chain/*genetics | 15 | 10.0 |
Lymphoma, Follicular/*genetics | 10 | 52.0 |
Polymerase Chain Reaction/*methods | 4 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/*genetics | 16 | 22.0 |
Apoptosis/*genetics | 9 | 3.0 |
Case-Control Studies | 4 | 0.0 |
Cyclin-Dependent Kinases/genetics | 2 | 3.0 |
DNA, Neoplasm/analysis | 11 | 1.0 |
DNA-Binding Proteins/genetics | 9 | 1.0 |
Membrane Proteins/genetics | 2 | 0.0 |
Polymerase Chain Reaction/methods | 6 | 0.0 |
*Proto-Oncogene Proteins | 2 | 0.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Transcription Factors/genetics | 9 | 1.0 |
Acute Disease | 3 | 0.0 |
*Adaptor Proteins, Signal Transducing | 2 | 0.0 |
*Gene Expression Profiling | 7 | 1.0 |
Genes, bcl-2/genetics/physiology | 2 | 50.0 |
Leukemia, Myeloid/*genetics | 2 | 1.0 |
Oncogene Proteins/genetics | 3 | 4.0 |
RNA/metabolism | 3 | 0.0 |
Enzyme Inhibitors/pharmacology | 15 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/genetics/metabolism | 7 | 12.0 |
*Down-Regulation | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 29 | 1.0 |
Protein p53/metabolism | 13 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/*biosynthesis/genetics | 3 | 8.0 |
Cell Survival/*physiology | 2 | 3.0 |
In Situ Nick-End Labeling | 20 | 3.0 |
*Protein-Serine-Threonine Kinases | 3 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 13 | 1.0 |
Antineoplastic Agents/pharmacology | 9 | 1.0 |
Antineoplastic Agents, Phytogenic/pharmacology | 6 | 6.0 |
Apoptosis | 27 | 1.0 |
Cell Division | 27 | 0.0 |
Cell Nucleus/metabolism | 5 | 0.0 |
Cloning, Molecular | 16 | 0.0 |
Cysteine Endopeptidases/*metabolism | 4 | 1.0 |
DNA, Complementary/metabolism | 5 | 0.0 |
Microscopy, Confocal | 6 | 0.0 |
Microscopy, Fluorescence | 5 | 0.0 |
Multienzyme Complexes/*metabolism | 3 | 2.0 |
Paclitaxel/pharmacology | 7 | 7.0 |
Prostatic Neoplasms/metabolism | 2 | 3.0 |
Proteasome Endopeptidase Complex | 4 | 0.0 |
Serine/metabolism | 4 | 1.0 |
Transfection | 34 | 0.0 |
Cells, Cultured | 23 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 5 | 0.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
Adolescent | 28 | 0.0 |
Child | 20 | 0.0 |
DNA-Binding Proteins/*genetics | 7 | 0.0 |
*Gene Rearrangement | 17 | 6.0 |
Lymphoma, B-Cell/*genetics/mortality | 3 | 75.0 |
Lymphoma, Large-Cell, Diffuse/*genetics/mortality | 4 | 100.0 |
Proto-Oncogene Proteins/*genetics | 40 | 4.0 |
Retrospective Studies | 13 | 0.0 |
Survival Rate | 14 | 0.0 |
Transcription Factors/*genetics | 7 | 0.0 |
Cell Differentiation | 12 | 0.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Neoplasm Proteins/*physiology | 3 | 3.0 |
Proto-Oncogene Proteins c-bcl-2/*physiology | 5 | 20.0 |
Gene Expression | 20 | 0.0 |
Gene Therapy/*methods | 3 | 0.0 |
*Genes, bcl-2 | 22 | 33.0 |
Rats | 14 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Vascular Endothelial Growth Factor A | 3 | 0.0 |
Vascular Endothelial Growth Factors | 3 | 0.0 |
Breast Neoplasms/*pathology | 3 | 1.0 |
Cell Cycle | 4 | 0.0 |
Disease Progression | 5 | 0.0 |
Kinetics | 11 | 0.0 |
Ligands | 3 | 0.0 |
Protein p53/*biosynthesis/genetics | 3 | 8.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Dimerization | 2 | 0.0 |
Etoposide/pharmacology | 5 | 3.0 |
HL-60 Cells | 11 | 1.0 |
Mitochondria/metabolism | 5 | 1.0 |
Plasmids/metabolism | 2 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Cell Transformation, Neoplastic/genetics | 5 | 1.0 |
*Chromosome Aberrations | 11 | 1.0 |
Chromosomes, Human, Pair 15 | 2 | 1.0 |
Chromosomes, Human, Pair 17 | 3 | 0.0 |
Chromosomes, Human, Pair 8 | 6 | 4.0 |
Comparative Study | 45 | 0.0 |
Karyotyping | 25 | 1.0 |
Leukemia, Promyelocytic, Acute/*genetics | 2 | 4.0 |
Neoplasm Proteins/*genetics/metabolism | 2 | 1.0 |
Oncogene Proteins, Fusion/*genetics/metabolism | 3 | 13.0 |
Recurrence | 5 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 4 | 0.0 |
Biopsy | 7 | 0.0 |
Cyclophosphamide/administration & dosage | 2 | 0.0 |
Immunoenzyme Techniques | 13 | 0.0 |
Neoplasm Staging | 18 | 0.0 |
Paclitaxel/*analogs & derivatives/*therapeutic use | 2 | 66.0 |
*Taxoids | 4 | 7.0 |
Tumor Markers, Biological/metabolism | 8 | 2.0 |
Cytochrome c Group/*metabolism | 2 | 6.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
*Proto-Oncogene Proteins c-bcl-2 | 5 | 1.0 |
Reproducibility of Results | 2 | 0.0 |
Chromosome Banding | 8 | 1.0 |
Cyclin D1/genetics | 4 | 6.0 |
Cytogenetic Analysis | 5 | 4.0 |
Genes, Immunoglobulin/*genetics | 2 | 4.0 |
Lymphoma, B-Cell/*genetics | 19 | 27.0 |
Lymphoma, Follicular/genetics | 8 | 72.0 |
Polymerase Chain Reaction | 29 | 0.0 |
Proto-Oncogene Proteins/genetics | 16 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/genetics | 15 | 14.0 |
Proto-Oncogene Proteins c-myc/genetics | 2 | 3.0 |
Lymphoma, Large-Cell, Diffuse/*genetics | 7 | 30.0 |
*Chromosome Breakage | 3 | 8.0 |
Chromosome Walking | 2 | 4.0 |
Chromosomes, Human, Pair 14/genetics/*ultrastructure | 2 | 33.0 |
DNA Nucleotidyltransferases/metabolism | 2 | 8.0 |
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 4 | 6.0 |
Translocation, Genetic/*genetics | 11 | 5.0 |
VDJ Recombinases | 4 | 6.0 |
Cell Division/genetics | 3 | 0.0 |
RNA, Messenger/analysis | 8 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 4 | 0.0 |
Chemotherapy, Adjuvant | 4 | 1.0 |
Cytogenetics | 3 | 3.0 |
Neoplasm Recurrence, Local | 3 | 0.0 |
Survival Analysis | 23 | 1.0 |
Tumor Markers, Biological/analysis | 7 | 0.0 |
Gene Rearrangement/genetics | 2 | 4.0 |
Lymphoma, Large-Cell/*genetics | 2 | 33.0 |
Nucleic Acid Hybridization/methods | 2 | 2.0 |
Polymorphism, Single-Stranded Conformational | 9 | 0.0 |
Proto-Oncogene Proteins/biosynthesis/genetics | 2 | 2.0 |
B-Lymphocytes/*ultrastructure | 2 | 33.0 |
DNA, Neoplasm/genetics | 13 | 1.0 |
Germinal Center/*pathology | 3 | 75.0 |
Lymphoma, Follicular/*genetics/pathology | 7 | 100.0 |
Oncogene Proteins, Fusion/*genetics | 4 | 2.0 |
RNA, Messenger/genetics | 8 | 0.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 22 | 0.0 |
Apoptosis/drug effects | 6 | 0.0 |
DNA Fragmentation | 9 | 2.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 3 | 1.0 |
Gene Therapy | 2 | 0.0 |
Neoplasm Proteins/*biosynthesis/genetics | 3 | 1.0 |
Plasmids/genetics | 2 | 0.0 |
Tumor Cells, Cultured/drug effects | 4 | 0.0 |
Chromosomes, Human, Pair 14/*genetics | 5 | 5.0 |
Chromosomes, Human, Pair 18/*genetics | 8 | 10.0 |
English Abstract | 19 | 0.0 |
Interphase/genetics | 2 | 14.0 |
Lymphoma, Non-Hodgkin/genetics/pathology | 2 | 28.0 |
Caspases/genetics | 2 | 8.0 |
Cell Line | 31 | 0.0 |
Cytoplasm/metabolism | 5 | 0.0 |
Hela Cells | 4 | 0.0 |
*MAP Kinase Kinase Kinase 1 | 2 | 1.0 |
Protein-Serine-Threonine Kinases/*metabolism | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Cell Cycle/genetics | 3 | 2.0 |
Cyclins/genetics | 4 | 2.0 |
DNA, Complementary/genetics | 6 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
*Chromosomes, Human, Pair 1 | 3 | 0.0 |
*Gene Expression Regulation | 4 | 0.0 |
Gene Rearrangement | 12 | 2.0 |
In Situ Hybridization, Fluorescence/methods | 3 | 3.0 |
Lymphoma, Non-Hodgkin/genetics | 3 | 23.0 |
Mutagenesis, Insertional | 2 | 0.0 |
*Chromosome Deletion | 4 | 0.0 |
Life Tables | 4 | 2.0 |
Nucleic Acid Hybridization | 12 | 0.0 |
Risk Factors | 8 | 0.0 |
S Phase | 2 | 0.0 |
Blotting, Southern | 15 | 0.0 |
Immunophenotyping | 19 | 0.0 |
Biological Markers | 9 | 0.0 |
In Vitro | 6 | 0.0 |
Protein p53/analysis | 19 | 6.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 26 | 13.0 |
Cell Transformation, Neoplastic/*pathology | 2 | 7.0 |
Lymphoma, Follicular/*pathology | 2 | 66.0 |
Protein p53/genetics | 7 | 4.0 |
Chromosome Mapping | 15 | 0.0 |
Ki-67 Antigen/*analysis | 3 | 4.0 |
Multivariate Analysis | 11 | 0.0 |
Receptors, Estrogen/analysis | 4 | 1.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Antigens, CD95/physiology | 2 | 2.0 |
DNA-Binding Proteins/*genetics/metabolism | 2 | 0.0 |
*Milk Proteins | 2 | 0.0 |
Sequence Deletion | 2 | 0.0 |
U937 Cells | 3 | 0.0 |
Biological Markers/analysis | 5 | 0.0 |
Remission Induction | 6 | 1.0 |
Mice, Inbred BALB C | 6 | 0.0 |
Mice, Nude | 12 | 0.0 |
Neoplasm Transplantation | 10 | 0.0 |
Transplantation, Heterologous | 9 | 0.0 |
Cytokines/blood | 3 | 1.0 |
DNA Primers | 8 | 0.0 |
Prostaglandin-Endoperoxide Synthase/genetics/*metabolism | 2 | 9.0 |
*Chromosomes, Human, Pair 11 | 5 | 0.0 |
Gene Expression Profiling | 8 | 0.0 |
Genetic Markers | 8 | 0.0 |
RNA, Neoplasm/biosynthesis | 2 | 1.0 |
Cyclins/*biosynthesis | 2 | 3.0 |
Epithelial Cells/physiology | 2 | 2.0 |
Infant | 7 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Ki-67 Antigen/*biosynthesis | 2 | 7.0 |
*Muscle Proteins | 2 | 0.0 |
Protein p53/*biosynthesis | 5 | 4.0 |
Proto-Oncogene Proteins/*biosynthesis | 2 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/*biosynthesis | 12 | 11.0 |
In Situ Hybridization | 7 | 0.0 |
Proto-Oncogene Proteins/biosynthesis | 4 | 2.0 |
Chromosomes, Human, Pair 18/*genetics/ultrastructure | 2 | 22.0 |
Exons/genetics | 2 | 0.0 |
Immunoglobulins, lambda-Chain/genetics | 2 | 14.0 |
Introns/genetics | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Immunoblotting | 3 | 0.0 |
*Tumor Cells, Cultured | 3 | 4.0 |
Luciferases/genetics | 2 | 0.0 |
Plasmids | 5 | 0.0 |
DNA-Binding Proteins/analysis | 4 | 5.0 |
Ki-67 Antigen/analysis | 8 | 2.0 |
Proto-Oncogene Proteins/analysis | 11 | 5.0 |
Transcription Factors/analysis | 4 | 5.0 |
Interphase | 6 | 3.0 |
*Oncogenes | 17 | 4.0 |
DNA Primers/chemistry | 7 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis/genetics | 2 | 4.0 |
MAP Kinase Signaling System | 3 | 1.0 |
Mitogen-Activated Protein Kinases/physiology | 2 | 1.0 |
Signal Transduction/*physiology | 5 | 0.0 |
Caspases/*metabolism | 3 | 1.0 |
Enzyme Activation | 14 | 0.0 |
Antibodies, Monoclonal/*therapeutic use | 2 | 0.0 |
Poly(ADP-ribose) Polymerases/metabolism | 4 | 3.0 |
Proteins/genetics/metabolism | 2 | 1.0 |
*Radioimmunotherapy | 2 | 7.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 19 | 0.0 |
Lymph Nodes/pathology | 7 | 2.0 |
Antigens, CD95/analysis | 3 | 9.0 |
Antimetabolites, Antineoplastic/pharmacology | 2 | 2.0 |
*Arabidopsis Proteins | 2 | 2.0 |
Caspases/analysis | 2 | 10.0 |
Computer Systems | 2 | 3.0 |
Fatty Acid Desaturases/analysis | 2 | 66.0 |
Neoplasm Proteins/*analysis | 3 | 0.0 |
Chi-Square Distribution | 5 | 0.0 |
Neoplasm Proteins/genetics/*metabolism | 2 | 1.0 |
Transcription Factors/genetics/*metabolism | 3 | 0.0 |
Adenoviridae/genetics | 3 | 0.0 |
Apoptosis/genetics | 10 | 4.0 |
Gene Transfer Techniques | 2 | 0.0 |
*Genes, p53 | 7 | 1.0 |
Genetic Vectors | 9 | 0.0 |
Drug Synergism | 4 | 0.0 |
Phosphodiesterase Inhibitors/*pharmacology | 2 | 4.0 |
Cisplatin/*pharmacology | 4 | 3.0 |
Glutathione/metabolism | 5 | 2.0 |
Ovarian Neoplasms/*metabolism | 2 | 3.0 |
Child, Preschool | 11 | 0.0 |
Fetus | 3 | 0.0 |
Gestational Age | 3 | 0.0 |
Clone Cells | 4 | 0.0 |
Incidence | 2 | 0.0 |
Mastectomy | 2 | 2.0 |
Necrosis | 5 | 1.0 |
Receptor, erbB-2/analysis | 3 | 3.0 |
Receptors, Progesterone/analysis | 2 | 0.0 |
Tumor Markers, Biological/*analysis | 10 | 1.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Analysis of Variance | 4 | 0.0 |
Cohort Studies | 4 | 0.0 |
Retinoblastoma Protein/metabolism | 2 | 0.0 |
Treatment Outcome | 10 | 0.0 |
Viral Matrix Proteins/*metabolism | 2 | 8.0 |
Genes, bcl-2/genetics | 5 | 13.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*genetics | 2 | 0.0 |
Ki-67 Antigen/metabolism | 4 | 1.0 |
Lymph Nodes/metabolism/*pathology | 2 | 12.0 |
Alleles | 6 | 0.0 |
DNA, Neoplasm | 2 | 1.0 |
Leukemia, Lymphocytic, Acute/*genetics | 2 | 2.0 |
Apoptosis/*drug effects/physiology | 5 | 4.0 |
Gene Expression/drug effects | 4 | 0.0 |
Loss of Heterozygosity | 4 | 0.0 |
*Mutation | 7 | 0.0 |
Neoplasm Proteins/metabolism | 3 | 0.0 |
Proto-Oncogenes/*genetics | 3 | 4.0 |
Homeostasis | 2 | 0.0 |
Reference Values | 6 | 0.0 |
Sex Characteristics | 2 | 0.0 |
Neoplasm Recurrence, Local/genetics/pathology | 2 | 20.0 |
Paraffin Embedding | 2 | 0.0 |
Cell Communication | 2 | 0.0 |
Apoptosis/*radiation effects | 2 | 4.0 |
Cell Culture Techniques | 2 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 3 | 0.0 |
Estradiol/pharmacology | 2 | 0.0 |
Receptors, Estrogen/metabolism | 2 | 0.0 |
Tamoxifen/*pharmacology | 2 | 3.0 |
Combined Modality Therapy | 6 | 0.0 |
Disease-Free Survival | 11 | 1.0 |
Actins/analysis | 2 | 1.0 |
Antigens, CD/analysis | 3 | 0.0 |
*Gene Expression | 5 | 0.0 |
Neoplasm Metastasis | 3 | 0.0 |
*Nuclear Proteins | 8 | 0.0 |
Proto-Oncogene Proteins/analysis/*genetics | 2 | 4.0 |
Vimentin/analysis | 3 | 1.0 |
Mutagenesis | 3 | 0.0 |
I-kappa B/metabolism | 2 | 2.0 |
Cell Death | 3 | 0.0 |
DNA Damage | 7 | 0.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
*Drosophila Proteins | 2 | 0.0 |
Tumor Markers, Biological/*metabolism | 5 | 1.0 |
Cell Death/*physiology | 2 | 5.0 |
Culture Media | 3 | 0.0 |
Hydrogen Peroxide/metabolism | 2 | 1.0 |
Oxidative Stress | 4 | 1.0 |
Caspases/metabolism | 5 | 0.0 |
Membrane Glycoproteins/*metabolism | 2 | 0.0 |
DNA Primers/genetics | 3 | 0.0 |
Down-Regulation | 4 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Oxidation-Reduction | 2 | 0.0 |
MAP Kinase Signaling System/physiology | 2 | 2.0 |
Mitogen-Activated Protein Kinase 3 | 4 | 0.0 |
Models, Biological | 5 | 0.0 |
Protein Kinase C/antagonists & inhibitors/physiology | 2 | 9.0 |
Protein-Serine-Threonine Kinases/*physiology | 2 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/chemistry/*metabolism | 3 | 50.0 |
Staurosporine/pharmacology | 5 | 2.0 |
Structure-Activity Relationship | 2 | 0.0 |
Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Helminth Proteins/*pharmacology | 2 | 50.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins c-myc/genetics/*metabolism | 2 | 4.0 |
Immunohistochemistry/methods | 3 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis | 9 | 6.0 |
Cyclin D1/metabolism | 2 | 1.0 |
Retinoblastoma Protein/*metabolism | 2 | 1.0 |
5' Untranslated Regions/genetics | 2 | 1.0 |
Gene Frequency | 2 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Chromosomes, Human, Pair 3/genetics | 2 | 1.0 |
Proto-Oncogene Proteins/*genetics/metabolism | 2 | 1.0 |
Translocation, Genetic/genetics | 4 | 4.0 |
Cluster Analysis | 2 | 1.0 |
Protein p53/physiology | 2 | 2.0 |
Sensitivity and Specificity | 4 | 0.0 |
Proliferating Cell Nuclear Antigen/metabolism | 3 | 1.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 6 | 1.0 |
Trans-Activation (Genetics) | 4 | 0.0 |
Fluorescent Dyes | 2 | 0.0 |
Genes, p53 | 4 | 0.0 |
Point Mutation | 2 | 0.0 |
Restriction Mapping | 16 | 0.0 |
Acetylcysteine/pharmacology | 2 | 2.0 |
Cell Cycle/*drug effects | 2 | 1.0 |
Cyclins/*metabolism | 4 | 1.0 |
Blotting, Northern | 8 | 0.0 |
Proto-Oncogene Proteins/genetics/metabolism | 3 | 1.0 |
Reactive Oxygen Species/metabolism | 3 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 5 | 0.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 3 | 0.0 |
Protein Kinase C/metabolism | 4 | 0.0 |
Calcium/metabolism | 2 | 0.0 |
Antigens, CD95/metabolism | 2 | 1.0 |
Microscopy, Electron | 4 | 0.0 |
Cell Transformation, Neoplastic/*genetics | 2 | 1.0 |
Chromosome Aberrations/*genetics | 4 | 2.0 |
Chromosomes, Human, Pair 18 | 18 | 16.0 |
Chromosomes, Human, Pair 2 | 3 | 1.0 |
*Nucleic Acid Hybridization | 2 | 3.0 |
Antibodies, Monoclonal | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 11 | 0.0 |
Lymphoma, B-Cell/*pathology | 3 | 13.0 |
Neoplasm Proteins/analysis | 8 | 2.0 |
RNA, Neoplasm/analysis | 3 | 1.0 |
Amino Acid Sequence | 11 | 0.0 |
Binding Sites | 7 | 0.0 |
Cell Line, Tumor | 15 | 0.0 |
Dogs | 2 | 0.0 |
Hamsters | 3 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 4 | 0.0 |
Okadaic Acid/pharmacology | 3 | 3.0 |
*Gene Rearrangement, B-Lymphocyte | 5 | 19.0 |
Genes, bcl-1 | 2 | 15.0 |
Lymphoma, Large-Cell, Diffuse/*diagnosis/metabolism/mortality | 2 | 100.0 |
Repressor Proteins/analysis/*genetics | 2 | 100.0 |
Tumor Markers, Biological/analysis/*genetics | 3 | 14.0 |
*Tumor Markers, Biological | 2 | 1.0 |
*Cell Cycle Proteins | 3 | 0.0 |
Protein p53/analysis/*biosynthesis | 2 | 9.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
Protein Kinase C/*metabolism | 3 | 1.0 |
Cell Cycle/*physiology | 4 | 1.0 |
G2 Phase | 3 | 1.0 |
Mitosis | 3 | 0.0 |
Nocodazole/pharmacology | 3 | 2.0 |
Tetradecanoylphorbol Acetate/pharmacology | 5 | 0.0 |
Vinblastine/pharmacology | 2 | 5.0 |
Proto-Oncogene Proteins c-bcl-2/*analysis | 10 | 11.0 |
Soft Tissue Neoplasms/*genetics/metabolism/pathology | 2 | 40.0 |
Prevalence | 2 | 0.0 |
Risk Assessment | 4 | 0.0 |
Mifepristone/pharmacology | 2 | 2.0 |
Proto-Oncogene Proteins/physiology | 2 | 1.0 |
JNK Mitogen-Activated Protein Kinases | 8 | 1.0 |
Lymphatic Metastasis | 3 | 0.0 |
COS Cells | 2 | 0.0 |
beta-Galactosidase/genetics/metabolism | 2 | 3.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Signal Transduction/physiology | 3 | 0.0 |
Proto-Oncogene Proteins/*analysis | 9 | 5.0 |
*Membrane Proteins | 2 | 0.0 |
Chromosomes, Human, Pair 14 | 17 | 10.0 |
Exons | 3 | 0.0 |
Jurkat Cells | 3 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Antineoplastic Agents/chemistry/*pharmacology | 2 | 8.0 |
*Drug Resistance, Neoplasm | 3 | 1.0 |
Gene Expression Regulation, Neoplastic/genetics | 2 | 1.0 |
Genotype | 6 | 0.0 |
Bayes Theorem | 2 | 3.0 |
Antigens, CD44/analysis | 2 | 2.0 |
Antigens, Neoplasm/analysis | 3 | 0.0 |
Cell Cycle Proteins/physiology | 2 | 5.0 |
*Genes, Tumor Suppressor | 6 | 0.0 |
Leiomyosarcoma/*chemistry/genetics | 2 | 100.0 |
Monosaccharide Transport Proteins/analysis | 2 | 33.0 |
Uterine Neoplasms/*chemistry/genetics | 2 | 100.0 |
DNA Probes | 8 | 0.0 |
Tonsil/pathology | 2 | 12.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
Bone Marrow Transplantation | 3 | 1.0 |
*Cell Transformation, Viral | 3 | 1.0 |
Mitogen-Activated Protein Kinases/metabolism | 6 | 0.0 |
NF-kappa B/metabolism | 2 | 0.0 |
Proteins/metabolism | 3 | 0.0 |
Cell Size/drug effects | 2 | 2.0 |
Cell Line, Tumor/cytology/drug effects/metabolism | 2 | 40.0 |
Cisplatin/pharmacology | 3 | 1.0 |
Flavonoids/pharmacology | 4 | 1.0 |
Signal Transduction/drug effects | 4 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Phosphorylation/drug effects | 7 | 0.0 |
Italy/epidemiology | 2 | 0.0 |
Leukocyte Count | 2 | 0.0 |
Mitotic Index | 2 | 1.0 |
Tetrahydrofolate Dehydrogenase/genetics | 2 | 2.0 |
Tumor Stem Cell Assay | 2 | 1.0 |
Apoptosis/drug effects/*genetics | 3 | 9.0 |
*Ploidies | 2 | 2.0 |
Cell Cycle/*genetics | 3 | 4.0 |
Ceramides/*pharmacology | 2 | 10.0 |
Mitochondria/*enzymology | 2 | 1.0 |
Gamma Rays | 2 | 0.0 |
Gene Deletion | 4 | 0.0 |
Ultraviolet Rays | 6 | 0.0 |
3T3 Cells | 7 | 0.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Cyclin D1/analysis | 2 | 5.0 |
Receptor, Epidermal Growth Factor/analysis | 3 | 1.0 |
Microtubule-Associated Proteins/metabolism | 2 | 1.0 |
Hyperplasia | 2 | 0.0 |
Thyroid Gland/*pathology | 2 | 14.0 |
Chromosome Deletion | 6 | 0.0 |
Chromosomes, Human, Pair 3 | 3 | 1.0 |
*Gene Amplification | 5 | 1.0 |
*Mitogen-Activated Protein Kinases | 4 | 1.0 |
*Radiation Tolerance | 3 | 5.0 |
*Linkage (Genetics) | 3 | 0.0 |
*Alternative Splicing | 2 | 0.0 |
DNA, Complementary | 4 | 0.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 2 | 0.0 |
*Cell Survival | 2 | 5.0 |
Growth Substances/pharmacology | 2 | 1.0 |
Drug Resistance | 4 | 0.0 |
Multidrug Resistance-Associated Proteins | 2 | 2.0 |
Cytarabine/pharmacology | 3 | 6.0 |
Hydrolysis | 2 | 0.0 |
Microtubules/*drug effects | 4 | 21.0 |
Cell Line, Transformed | 3 | 0.0 |
Adenoviridae | 2 | 2.0 |
Antigens, CD95 | 2 | 5.0 |
Lung Neoplasms/*pathology | 2 | 2.0 |
Dose-Response Relationship, Radiation | 3 | 0.0 |
Apoptosis/*drug effects/genetics | 2 | 6.0 |
DNA Mutational Analysis | 6 | 0.0 |
RNA Splicing | 2 | 0.0 |
*Apoptosis/genetics | 5 | 13.0 |
*DNA-Binding Proteins | 3 | 0.0 |
Gene Expression Regulation/drug effects | 4 | 0.0 |
Hematopoietic Stem Cells/*cytology | 2 | 0.0 |
Neoplasm Proteins/biosynthesis/*genetics | 2 | 2.0 |
Nuclear Proteins/*metabolism | 2 | 0.0 |
Transcription Factors/*metabolism | 3 | 0.0 |
Multiple Myeloma/*genetics | 2 | 4.0 |
Genes, Tumor Suppressor | 3 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Recombinant Fusion Proteins/genetics | 2 | 1.0 |
Oligonucleotide Array Sequence Analysis/*methods | 2 | 1.0 |
Vascular Endothelial Growth Factor A/metabolism | 2 | 1.0 |
Genes, Immunoglobulin | 9 | 4.0 |
*Genes, myc | 4 | 1.0 |
Neoplasm Proteins/biosynthesis/genetics | 2 | 1.0 |
*Signal Transduction | 3 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
*Genetic Heterogeneity | 2 | 1.0 |
Microsatellite Repeats | 2 | 0.0 |
Genes, ras | 2 | 0.0 |
Mice, SCID | 3 | 0.0 |
Doxorubicin/pharmacology | 2 | 0.0 |
Prostatic Neoplasms/*metabolism/pathology | 2 | 2.0 |
Neovascularization, Pathologic | 2 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 2 | 0.0 |
Cyclins/*analysis | 3 | 7.0 |
Protein p53/*analysis | 6 | 3.0 |
Radiation Tolerance | 2 | 2.0 |
Gene Expression Regulation, Neoplastic/*physiology | 2 | 1.0 |
Drug Resistance, Neoplasm/*genetics | 2 | 2.0 |
DNA-Binding Proteins/*biosynthesis | 2 | 1.0 |
Inhibitory Concentration 50 | 2 | 0.0 |
P-Glycoprotein/*biosynthesis | 2 | 6.0 |
Cell Cycle Proteins/*analysis | 2 | 11.0 |
Retinoblastoma Protein/analysis | 2 | 5.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Down-Regulation/drug effects | 2 | 0.0 |
Flavonoids/*pharmacology | 2 | 2.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 2 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Disease Models, Animal | 4 | 0.0 |
Genes, bcl-2/*physiology | 3 | 37.0 |
Genes, p53/*physiology | 3 | 6.0 |
Multigene Family | 3 | 0.0 |
Chromosome Disorders | 4 | 1.0 |
Cyclin D1 | 4 | 3.0 |
*Gene Rearrangement, B-Lymphocyte, Heavy Chain | 3 | 14.0 |
Carcinoma, Ductal, Breast/metabolism/pathology | 2 | 9.0 |
Cytosol/metabolism | 3 | 0.0 |
Ki-67 Antigen/biosynthesis | 3 | 3.0 |
Spodoptera | 2 | 0.0 |
Bone Marrow/pathology | 4 | 1.0 |
Chromosomes, Human, Pair 11 | 3 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/genetics/*physiology | 2 | 22.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
Gene Amplification | 2 | 0.0 |
Proto-Oncogenes/genetics | 2 | 6.0 |
Chromosomes, Human, Pair 14/ultrastructure | 2 | 33.0 |
Chronic Disease | 3 | 0.0 |
Leukemia, B-Cell/*genetics | 4 | 44.0 |
Lymph Nodes/*pathology | 2 | 2.0 |
Biopsy, Needle | 3 | 0.0 |
Diagnosis, Differential | 5 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
*Proto-Oncogenes | 24 | 3.0 |
*Chromosomes, Human, Pair 3 | 3 | 0.0 |
Zinc Fingers | 3 | 0.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Organ Specificity | 2 | 0.0 |
Radiation, Ionizing | 2 | 1.0 |
Proto-Oncogene Proteins/genetics/*physiology | 2 | 2.0 |
Sex Factors | 2 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Models, Molecular | 2 | 0.0 |
Caspase 1 | 2 | 5.0 |
Oncogenes | 3 | 1.0 |
DNA/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins/biosynthesis/*physiology | 2 | 12.0 |
Proto-Oncogene Proteins c-bcl-2 | 56 | 34.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
Morphogenesis | 2 | 0.0 |
Lymphoma, B-Cell/*genetics/immunology | 2 | 22.0 |
*Cell Cycle | 3 | 1.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Lymphoma, B-Cell/genetics | 2 | 11.0 |
Lymphoma, Non-Hodgkin/*genetics | 4 | 9.0 |
Paclitaxel/*pharmacology | 2 | 3.0 |
Neurites/drug effects/physiology | 2 | 13.0 |
Neurons/*cytology | 2 | 3.0 |
Proto-Oncogenes | 5 | 2.0 |
Cell Cycle/drug effects/genetics | 2 | 11.0 |
Tetracycline/pharmacology | 2 | 2.0 |
Carcinoma, Squamous Cell/*genetics/pathology | 2 | 3.0 |
Membrane Glycoproteins/biosynthesis | 2 | 1.0 |
Tumor Markers, Biological | 5 | 1.0 |
DNA, Mitochondrial/*genetics | 2 | 1.0 |
*Gene Deletion | 2 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Bone Marrow/*pathology | 2 | 1.0 |
Gene Expression/*physiology | 2 | 2.0 |
Neoplasms/genetics | 4 | 3.0 |
Oncogenes/*genetics | 2 | 2.0 |
Cell Count | 2 | 0.0 |
Cell Death/physiology | 2 | 2.0 |
Chromosomes, Human, Pair 14/*ultrastructure | 4 | 50.0 |
Chromosomes, Human, Pair 18/*ultrastructure | 5 | 50.0 |
DNA/genetics | 2 | 0.0 |
B-Lymphocytes/metabolism | 3 | 1.0 |
Oligodeoxyribonucleotides | 3 | 0.0 |
Gene Silencing | 2 | 0.0 |
Radiotherapy, Adjuvant | 2 | 2.0 |
Cytochromes c/metabolism | 2 | 3.0 |
Cell Cycle/drug effects | 3 | 0.0 |
GTP-Binding Proteins/genetics | 2 | 4.0 |
Proto-Oncogene Proteins/biosynthesis/*genetics | 2 | 3.0 |
Gene Expression Profiling/methods | 2 | 2.0 |
B-Lymphocytes | 2 | 1.0 |
Lymphoma/genetics | 2 | 8.0 |
Protein-Tyrosine Kinase/genetics | 7 | 6.0 |
DNA, Neoplasm/genetics/isolation & purification | 4 | 3.0 |
Neoplasm Proteins/*genetics | 3 | 0.0 |
Metaphase | 2 | 1.0 |
*Chromosomes, Human, Pair 22 | 3 | 1.0 |
*Recombination, Genetic | 3 | 0.0 |
B-Lymphocytes/*physiology | 2 | 1.0 |
Genome, Human | 2 | 0.0 |
*Chromosomes, Human, Pair 8 | 2 | 0.0 |
Leukemia/*genetics | 4 | 3.0 |
Proto-Oncogene Proteins c-myc | 3 | 7.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
Principal Component Analysis | 2 | 9.0 |
Nitric-Oxide Synthase/metabolism | 2 | 1.0 |
Protein p53/biosynthesis | 3 | 2.0 |
Protein p16/analysis | 2 | 10.0 |
Lymphoma, B-Cell/*metabolism/pathology | 2 | 13.0 |
Lymphoma, Large-Cell, Diffuse/*metabolism/pathology | 2 | 100.0 |
Neprilysin/*metabolism | 2 | 14.0 |
Cell Transformation, Neoplastic/genetics/pathology | 2 | 9.0 |
Transcription Factors/physiology | 2 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
Gene Expression Profiling/*methods | 2 | 2.0 |
